User profiles for "author:Sophie Piperno-Neumann"

sophie piperno-neumann

institut Curie
Verified email at curie.fr
Cited by 17356

Advances in the clinical management of uveal melanoma

RD Carvajal, JJ Sacco, MJ Jager… - Nature Reviews …, 2023 - nature.com
Melanomas arising in the uveal tract of the eye are a rare form of the disease with a biology
and clinical phenotype distinct from their more common cutaneous counterparts. Treatment …

[HTML][HTML] Metastatic uveal melanoma: The final frontier

ES Rantala, MM Hernberg, S Piperno-Neumann… - Progress in Retinal and …, 2022 - Elsevier
Abstract Treatment of primary intraocular uveal melanoma has developed considerably, its
driver genes are largely unraveled, and the ways to assess its risk for metastases are very …

[HTML][HTML] Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

S Stacchiotti, AB Miah, AM Frezza, C Messiou… - ESMO open, 2021 - Elsevier
Highlights•This consensus paper provides key recommendations on the management of
epithelioid hemangioendothelioma (EHE).•Recommendations followed a consensus …

[HTML][HTML] Overall survival benefit with tebentafusp in metastatic uveal melanoma

P Nathan, JC Hassel, P Rutkowski… - … England Journal of …, 2021 - Mass Medical Soc
Background Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a
low tumor mutational burden and a 1-year overall survival of approximately 50% in patients …

[PDF][PDF] Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

N Penel, BN Bui, JO Bay, D Cupissol, I Ray-Coquard… - J Clin Oncol, 2008 - academia.edu
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
Page 1 Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX …

Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial

M Toulmonde, N Penel, J Adam, C Chevreau… - JAMA …, 2018 - jamanetwork.com
Importance There is a strong rationale for treating sarcomas with immunotherapy. Objective
To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in …

SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma

SJ Furney, M Pedersen, D Gentien, AG Dumont… - Cancer discovery, 2013 - AACR
Uveal melanoma, the most common eye malignancy, causes severe visual morbidity and is
fatal in approximately 50% of patients. Primary uveal melanoma can be cured by surgery or …

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

A Italiano, A Bessede, M Pulido, E Bompas… - Nature medicine, 2022 - nature.com
Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced
soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary …

[HTML][HTML] Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage

S Alsafadi, A Houy, A Battistella, T Popova… - Nature …, 2016 - nature.com
Hotspot mutations in the spliceosome gene SF3B1 are reported in∼ 20% of uveal
melanomas. SF3B1 is involved in 3′-splice site (3′ ss) recognition during RNA splicing; …

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

O Mir, T Brodowicz, A Italiano, J Wallet, JY Blay… - The lancet …, 2016 - thelancet.com
Background Regorafenib is a multikinase inhibitor with proven activity in refractory
gastrointestinal stromal tumours and chemotherapy-refractory advanced colorectal cancers …